-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yinming Bio announced that the original small-molecule drug GGW0014 under development by its subsidiary, Gwitch, has completed the clinical filing of a new class of veterinary drug on March 17, 2022.
The drug is used to treat pruritus caused by allergic dermatitis in dogs and will be launched soon.
Clinical trials in China
.
GGW0014 is the second category 1.
1 new pet drug entered into clinical stage by GGW this year, and its first small molecule drug ZYF0033 for the treatment of feline infectious peritonitis entered the clinic in January this year
.